Truist analyst Srikripa Devarakonda raised the firm’s price target on MBX Biosciences (MBX) to $70 from $50 and keeps a Buy rating on the shares. The firm is updating its model ahead of multiple events and reflecting greater conviction in the management’s ability to execute on pipeline, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
- MBX Biosciences Highlights Positive Phase 1 Obesity Data
- Advancing Pipeline and Key Data Catalysts Drive Analyst’s Bullish View on MBX
- MBX Biosciences reports Q1 EPS (51c), consensus (58c)
- MBX Biosciences appoints Mark Soued as chief commercial officer.